November 11, 2016

President-elect Donald Trump on Friday softened his stance on his manifesto to "repeal and replace" the Affordable Care Act, The Wall Street Journal reported. Following his meeting with President Barack Obama, Trump suggested he may keep a few provisions, such as the ban on denying insurance based on pre-existing conditions and the provision allowing parents to extend coverage for their children. "I told [Pres. Obama] I will look at his suggestions, and out of respect, I will do that,” Trump told The Journal. “Either Obamacare will be amended, or repealed and replaced.” (The Wall Street Journal)

November 10, 2016

An HDA survey found that a majority of pharmaceutical manufacturers, 89%, indicated that distributors will start to receive serialized products before the DSCSA-mandated deadline.

November 10, 2016
The consortium said the redesign is part of its digital evolution to showcase its industry expertise and support its overall growth. 
November 9, 2016
Business Insider is reporting that as news that Donald Trump will be the 45th president sent stocks into an early Thursday tumble in Europe, by around 9:50 a.m. in London (4:50 a.m. EST), pharmaceutical stocks were rising, with Hikma Pharmaceuticals’s stock up 6% on the FTSE 100. Roche and Novartis saw stock increases over 4% and GSK saw a 1.8% bump. Jefferies pointed to hope that efforts to enact new pricing rules on drugs led the swell, telling Business Insider, “Sentiment towards the Healthcare sector ought to swing initially away from draconian fears over drug pricing.” (Business Insider)
 
 
November 8, 2016

The companies believe their submission has the potential to be the first of a proposed biosimilar for the drug in the United States. 

November 7, 2016
Ajanta’s generic will be available in 50- and 200-mg dosage strengths. 
November 7, 2016

Endo has announced the appointment of two key executive leadership team members, naming Terrance J. Coughlin its EVP and COO, and adding Tony Pera as the president of Endo’s U.S. generics company Par Pharmaceutical. 

November 7, 2016

The company will collaborate with Bluepharma to develop and distribute a generic product in a category with U.S. sales more than $75 million, according to QuintilesIMS data for the 12 months ended July 2016. 

November 7, 2016

Teva has gotten approval from the Food and Drug Administration for two generics of high blood pressure drugs, one of which it has launched. 

November 4, 2016

Camber Pharmaceuticals on Thursday announced the launch of its generics of Avodart (dutasteride) capsules and Levaquin (levofloxacin) tablets.

November 2, 2016

Ajanta has launched its generic of Azor, a high blood pressure treatment. 

November 2, 2016
The contraceptive had U.S. sales of $178.2 million for the 12 months ended June 2016, according to QuintilesIMS data. 
November 1, 2016

The drug  had U.S. sales of $911 million for the 12 months ended September 2016, according to QuintilesIMS data.

October 31, 2016

Under the agreement, AstraZeneca will continue to manufacture and supply the drug and its authorized generic to Aralex Ireland for at least 10 years, and it will continue to distribute the product until it is transferred, which could be up to nine months after closing. 

October 31, 2016

Camber Pharmaceuticals on Monday announced the launch of its Crestor (rosuvastatin) generic. The drug is indicated to treat high triglycerides and cholesterol.

October 28, 2016

The drug is indicated to temporarily relieve cold, flu, allergy or other breathing illness symptoms. 

October 28, 2016

The launch marks the first for a generic of Benicar and Benicar HCT, which have a combined market size of $1.8 billion, according to IMS Health data for the 12 months ended Aug. 31. 

October 28, 2016
Bloomberg BNA is reporting that the Food and Drug Administration’s director of the Center for Drug Evaluation and Research’s Office of New Drugs told an audience at the DIA Biosimilars Conference that manufacturers looking to submit an application for biosimilar approval should know what the FDA is looking for when evaluating a biosmilar for approval. Jenkins said that rather than the focus on safety and efficacy it places on standalone biologics, with biosimilars, it focvuses on how closely it resembles the reference product, something he called “a work in progress” for some drug makers. (Bloomberg BNA)
 
October 27, 2016

NEW YORK - The giant AT&T-Time Warner merger may bring individualized ads - already commonplace on such streaming services as Hulu or YouTube - to network television, The New York Times reported Wednesday. "If you believe in a future where the very, very fine targeting of households or individuals with specific messaging makes economic sense to do at scale, what this merger does is enable that by making more audience available to target in that way,” Rob Norman, chief digital officer of WPP's GroupM, told The Times. “The question will be: What is the premium for addressability for that level of targeting that the advertiser is willing to pay?” (The New York Times)

October 26, 2016

Dr. Reddy’s Laboratoreis and Gland Pharma have announced a strategic collaboration to market and distribute eight injectable generics. 

October 26, 2016

Aurobindo’s generic will be available in 1-, 2- and 3-mg dosage strengths. 

October 26, 2016

Among the reasons for the  name change was the organization’s expansion beyond its founders’ focus on biotechnology. 

October 25, 2016

ANI’s benztropine mesylate tablets will be available in 0.5-, 1-, and 2-mg dosage strengths. 

October 25, 2016

Genco’s multi-tenant warehouse solution allows multiple manufacturers to operate alongside one another in a single warehouse, using a designated space with a shared technology platform.